Prostate Cancer Symptoms Research

Prostate Cancer is a form of cancer that develops in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, there are cases of aggressive prostate cancers. The cancer cells may metastasize spread from the prostate to other parts of the body, particularly the bones and lymph nodes. Prostate cancer may cause pain, difficulty in urinating, problems during sexual intercourse, or erectile dysfunction. Other symptoms can potentially develop during later stages of the disease.

Rates of detection of prostate cancers vary widely across the world, with South and East Asia detecting less frequently than in Europe, and especially the United States. Prostate cancer tends to develop in men over the age of fifty and although it is one of the most prevalent types of cancer in men, many never have symptoms, undergo no therapy, and eventually die of other causes.

Tweet-for-Cash with SponsoredTweets

Cancer of the prostate is, in most cases, slow-growing, symptom-free, and since men with the condition are older they often die of causes unrelated to the prostate cancer, such as heart/circulatory disease, pneumonia, other unconnected cancers, or old age. About two-thirds of cases are slow growing, the other third more aggressive and fast developing.

Advanced Prostate Cancer Drug May Help at Earlier Stage

WEDNESDAY, May 16 (HealthDay News) -- A drug approved to treat advanced prostate cancer appears to help men who have localized high-risk prostate cancer if given before surgery.

Tokai Pharmaceuticals’ Galeterone Phase 1 Data in Patients with Advanced Prostate Cancer to be Presented at ASCO ...

Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that additional data from a Phase 1 safety and proof-of-concept study evaluating lead candidate, galeterone , in patients with castration-resistant prostate cancer will be highlighted in a poster presentation titled, “Phase I clinical trial of galeterone , a ...

Prostate Cancer? Why Radical Surgery/Robotic Prostatectomy is NOT For You

CORAL SPRINGS, Fla., May 17, 2012 /PRNewswire/ -- As the world's top urologists begin the 107th Annual AUA Meeting in Atlanta this Friday, one of the nation's top prostate cancer specialists is challenging ...

J&J drug shows promise in high-risk prostate cancer

(Reuters) - Adding Johnson & Johnson's advanced prostate cancer drug, Zytiga, to hormone therapy before surgery has been shown for the first time to eradicate tumors in some men with high-risk forms of the disease. The mid-stage trial found that six months of treatment with the combination therapy completely or nearly eliminated the cancer in a third of patients, all of whom had localized ...

Zytiga, a Prostate Cancer Drug, Does Well in Trial

In a small clinical trial, six months of treatment with the drug Zytiga, added to standard therapy, eliminated or nearly eliminated tumors in about one-third of men whose disease had not yet spread beyond the prostate gland.

J&J’s Zytiga Helps Eliminate Early-Stage Prostate Cancer

Johnson & Johnson (JNJ) ’s Zytiga, approved last year to treat metastatic prostate cancer, helped eliminate tumors in high-risk patients whose malignancy hadn’t yet spread beyond the prostate gland, a small study found.

Prostate Cancer Drug 'Should Be Given On NHS'

A drug to treat advanced prostate cancer should be given to patients on the NHS, a health watchdog has said.

U-turn on NHS prostate drug use

A prostate cancer drug, which can extend life by at least three months, is likely to now get approval for NHS use in England and Wales.

Britain to fund prostate cancer pill in U-turn

LONDON (Reuters) - Britain's drug watchdog has reversed a controversial decision not to fund a new prostate cancer pill that was developed in the country after maker Johnson & Johnson agreed a new discount on supplies to the UK state healthcare service. Zytiga, which is known chemically as abiraterone, was approved last year in Europe and the United States to treat advanced prostate cancer in ...

New Equation in Prostate Cancer Diagnosis Yields Best Answer Yet

NEW YORK, NY-- - World-renowned prostate surgeon, Dr. David Samadi, may soon have the equation he needs to strengthen his approach to personalized medicine and prostate cancer treatment . Researchers at ...

Source: